145 related articles for article (PubMed ID: 11417113)
21. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
[TBL] [Abstract][Full Text] [Related]
22. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
[TBL] [Abstract][Full Text] [Related]
24. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Legraverend M; Tunnah P; Noble M; Ducrot P; Ludwig O; Grierson DS; Leost M; Meijer L; Endicott J
J Med Chem; 2000 Apr; 43(7):1282-92. PubMed ID: 10753466
[TBL] [Abstract][Full Text] [Related]
27. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
29. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
31. Structure-based design of cyclin-dependent kinase inhibitors.
Davies TG; Pratt DJ; Endicott JA; Johnson LN; Noble ME
Pharmacol Ther; 2002; 93(2-3):125-33. PubMed ID: 12191605
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
33. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
34. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
36. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
[TBL] [Abstract][Full Text] [Related]
37. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
38. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
39. The use of CDK inhibitors in oncology: a pharmaceutical perspective.
Fischer PM
Cell Cycle; 2004 Jun; 3(6):742-6. PubMed ID: 15118410
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
